239 related articles for article (PubMed ID: 9581835)
1. A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy.
Carron CP; Meyer DM; Pegg JA; Engleman VW; Nickols MA; Settle SL; Westlin WF; Ruminski PG; Nickols GA
Cancer Res; 1998 May; 58(9):1930-5. PubMed ID: 9581835
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.
Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L
Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792
[TBL] [Abstract][Full Text] [Related]
3. SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity.
Wilkinson-Berka JL; Jones D; Taylor G; Jaworski K; Kelly DJ; Ludbrook SB; Willette RN; Kumar S; Gilbert RE
Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1600-5. PubMed ID: 16565398
[TBL] [Abstract][Full Text] [Related]
4. NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis.
Dormond O; Foletti A; Paroz C; Rüegg C
Nat Med; 2001 Sep; 7(9):1041-7. PubMed ID: 11533708
[TBL] [Abstract][Full Text] [Related]
5. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis.
Trikha M; Zhou Z; Timar J; Raso E; Kennel M; Emmell E; Nakada MT
Cancer Res; 2002 May; 62(10):2824-33. PubMed ID: 12019160
[TBL] [Abstract][Full Text] [Related]
6. Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide.
Erdreich-Epstein A; Shimada H; Groshen S; Liu M; Metelitsa LS; Kim KS; Stins MF; Seeger RC; Durden DL
Cancer Res; 2000 Feb; 60(3):712-21. PubMed ID: 10676658
[TBL] [Abstract][Full Text] [Related]
7. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats.
Santulli RJ; Kinney WA; Ghosh S; Decorte BL; Liu L; Tuman RW; Zhou Z; Huebert N; Bursell SE; Clermont AC; Grant MB; Shaw LC; Mousa SA; Galemmo RA; Johnson DL; Maryanoff BE; Damiano BP
J Pharmacol Exp Ther; 2008 Mar; 324(3):894-901. PubMed ID: 18083913
[TBL] [Abstract][Full Text] [Related]
8. Identification of CD47/integrin-associated protein and alpha(v)beta3 as two receptors for the alpha3(IV) chain of type IV collagen on tumor cells.
Shahan TA; Ziaie Z; Pasco S; Fawzi A; Bellon G; Monboisse JC; Kefalides NA
Cancer Res; 1999 Sep; 59(18):4584-90. PubMed ID: 10493512
[TBL] [Abstract][Full Text] [Related]
9. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
Beebe JS; Jani JP; Knauth E; Goodwin P; Higdon C; Rossi AM; Emerson E; Finkelstein M; Floyd E; Harriman S; Atherton J; Hillerman S; Soderstrom C; Kou K; Gant T; Noe MC; Foster B; Rastinejad F; Marx MA; Schaeffer T; Whalen PM; Roberts WG
Cancer Res; 2003 Nov; 63(21):7301-9. PubMed ID: 14612527
[TBL] [Abstract][Full Text] [Related]
11. Involvement of alpha(v)beta3 integrin-like receptor and glycosaminoglycans in Candida albicans germ tube adhesion to vitronectin and to a human endothelial cell line.
Santoni G; Spreghini E; Lucciarini R; Amantini C; Piccoli M
Microb Pathog; 2001 Oct; 31(4):159-72. PubMed ID: 11562169
[TBL] [Abstract][Full Text] [Related]
12. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
13. Studies on the expression of alpha(v)beta3 integrin receptors in non-malignant and malignant human cervical tumor tissues.
Chattopadhyay N; Chatterjee A
J Exp Clin Cancer Res; 2001 Jun; 20(2):269-75. PubMed ID: 11484986
[TBL] [Abstract][Full Text] [Related]
14. Cytokines modulate integrin alpha(v)beta(3)-mediated human endothelial cell adhesion and calcium signaling.
Yeh CH; Peng HC; Huang TF
Exp Cell Res; 1999 Aug; 251(1):57-66. PubMed ID: 10438571
[TBL] [Abstract][Full Text] [Related]
15. Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival.
Petitclerc E; Strömblad S; von Schalscha TL; Mitjans F; Piulats J; Montgomery AM; Cheresh DA; Brooks PC
Cancer Res; 1999 Jun; 59(11):2724-30. PubMed ID: 10363998
[TBL] [Abstract][Full Text] [Related]
16. Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis.
Lark MW; Stroup GB; Hwang SM; James IE; Rieman DJ; Drake FH; Bradbeer JN; Mathur A; Erhard KF; Newlander KA; Ross ST; Salyers KL; Smith BR; Miller WH; Huffman WF; Gowen M
J Pharmacol Exp Ther; 1999 Nov; 291(2):612-7. PubMed ID: 10525079
[TBL] [Abstract][Full Text] [Related]
17. Novel small molecule alpha v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors.
Kerr JS; Wexler RS; Mousa SA; Robinson CS; Wexler EJ; Mohamed S; Voss ME; Devenny JJ; Czerniak PM; Gudzelak A; Slee AM
Anticancer Res; 1999; 19(2A):959-68. PubMed ID: 10368639
[TBL] [Abstract][Full Text] [Related]
18. Contortrostatin, a homodimeric snake venom disintegrin, is a potent inhibitor of osteoclast attachment.
Mercer B; Markland F; Minkin C
J Bone Miner Res; 1998 Mar; 13(3):409-14. PubMed ID: 9525341
[TBL] [Abstract][Full Text] [Related]
19. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 2: synthesis of potent alpha(v)beta3/alpha(IIb)beta3 dual antagonists.
Ishikawa M; Kubota D; Yamamoto M; Kuroda C; Iguchi M; Koyanagi A; Murakami S; Ajito K
Bioorg Med Chem; 2006 Apr; 14(7):2109-30. PubMed ID: 16309912
[TBL] [Abstract][Full Text] [Related]
20. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice.
Reinmuth N; Liu W; Ahmad SA; Fan F; Stoeltzing O; Parikh AA; Bucana CD; Gallick GE; Nickols MA; Westlin WF; Ellis LM
Cancer Res; 2003 May; 63(9):2079-87. PubMed ID: 12727823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]